Immunofoco Biotechnology Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 105

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 26

Immunofoco Biotechnology General Information

Description

Developer and manufacturer of CAR-T cell therapies and innovative treatment platforms designed for solid tumors and hematological cancers. The company provides clinical-stage drug candidates and off-the-shelf solutions, enabling oncology patients and healthcare providers with enhanced therapeutic options, improved survival outcomes, and more accessible cellular immunotherapy.

Contact Information

Website
immunofoco.com
Formerly Known As
Immuno Head, Shanghai Immunohead Biotechnology Co.,Ltd, Immunohead, Immunohead Biotechnology, Suzhou Immunofoco Biotechnology Co., Ltd., Shenzhen Yimufeng Biotechnology Co., Ltd.
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • 3rd Floor, Building 4
  • No. 11 Galileo Road, China (China) Pilot Free Trade Zone
  • Shanghai, 201210
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 3rd Floor, Building 4
  • No. 11 Galileo Road, China (China) Pilot Free Trade Zone
  • Shanghai, 201210
  • China
+86 021

Immunofoco Biotechnology Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunofoco Biotechnology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. IPO 13-Feb-2026 Announced Generating Revenue
9. Later Stage VC (Series C) 09-Feb-2026 Completed Generating Revenue
8. Secondary Transaction - Private 19-Dec-2025 Completed Generating Revenue
7. Later Stage VC (Series B) 28-Nov-2025 Completed Generating Revenue
6. Later Stage VC (Series A2) 25-Sep-2025 Completed Generating Revenue
5. Early Stage VC (Series A1) 11-Oct-2023 Completed Clinical Trials - Phase 1
4. Secondary Transaction - Private 02-Mar-2022 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 02-Mar-2022 Completed Pre-Clinical Trials
2. Seed Round 29-Apr-2021 $2.3M $3.83M Completed Startup
1. Seed Round 18-Jan-2021 $1.54M $1.54M Completed Startup
To view Immunofoco Biotechnology’s complete valuation and funding history, request access »

Immunofoco Biotechnology Patents

  • 11

    Total Documents Applications and Grants

  • Total Patents Families

  • 1

    Granted

  • 6

    Pending

  • Expiring in next 12 mo

Immunofoco Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026130330-A1 Modified feeder cell and use thereof Pending 18-Dec-2024
WO-2025242065-A1 Method for predicting solid tumor immune cell therapy treatment response Pending 23-May-2024
WO-2025011270-A1 T-cell culture method Inactive 13-Jul-2023
US-20250319129-A1 Chimeric antigen receptor containing cldn18.2 single domain antibody and application thereof Pending 27-May-2022
US-20240316105-A1 Novel chimeric receptor composition, recombinant vector, cell, and application thereof Pending 14-Jul-2021 A61K35/17
To view Immunofoco Biotechnology’s complete patent history, request access »

Immunofoco Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunofoco Biotechnology Investors (26)

Investor Name Investor Type Holding Investor Since Participating Rounds
Gaorong Ventures Venture Capital Minority
Jifeng Ventures Venture Capital Minority
Mingdao Investment Growth/Expansion Minority
Shenzhen Angel Investment Guiding Fund Fund of Funds Minority
Fosun Health Capital Corporate Venture Capital Minority
You’re viewing 5 of 26 investors. Get the full list »

Ready to get started?

Request a free trial

Immunofoco Biotechnology FAQs

  • When was Immunofoco Biotechnology founded?

    Immunofoco Biotechnology was founded in 2020.

  • Where is Immunofoco Biotechnology headquartered?

    Immunofoco Biotechnology is headquartered in Shanghai, China.

  • What is the size of Immunofoco Biotechnology?

    Immunofoco Biotechnology has 105 total employees.

  • What industry is Immunofoco Biotechnology in?

    Immunofoco Biotechnology’s primary industry is Drug Discovery.

  • Is Immunofoco Biotechnology a private or public company?

    Immunofoco Biotechnology is a Private company.

  • What is Immunofoco Biotechnology’s current revenue?

    The current revenue for Immunofoco Biotechnology is .

  • How much funding has Immunofoco Biotechnology raised over time?

    Immunofoco Biotechnology has raised $139M.

  • Who are Immunofoco Biotechnology’s investors?

    Gaorong Ventures, Jifeng Ventures, Mingdao Investment, Shenzhen Angel Investment Guiding Fund, and Fosun Health Capital are 5 of 26 investors who have invested in Immunofoco Biotechnology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process